logo-loader
viewLineage Cell Therapeutics

Lineage Cell Therapeutics busy working on treatments relating to Dry AMD and spinal cord injury

Lineage Cell Therapeutics (NYSE AMERICAN: LCTX) CEO Brian Culley and CFO Brandi Roberts joined Steve Darling from Proactive to share details about their proprietary cell-based therapy platform. The Company is using that platform to advance a pipeline of novel candidates for the treatment of advanced dry age-related macular degeneration, spinal cord injuries, and cancer.

Both Culley and Roberts discussed recent clinical developments and provided an overview of the Company’s balance sheet. Lineage will be a featured company on Proactive’s next One2One Virtual conferences.

Quick facts: Lineage Cell Therapeutics

Price: 2.17 USD

NYSE:LCTX
Market: NYSE
Market Cap: $325.48 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lineage Cell Therapeutics named herein, including the promotion by the Company of Lineage Cell Therapeutics in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Lineage Cell Therapeutics presents at the Proactive One2One virtual...

Brian Culley, CEO of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) and CFO Brandi Roberts present to investors at the Proactive One2One virtual investment forum. California-based Lineage Cell Therapeutics is a clinical-stage biotechnology company that is...

on 8/12/20

2 min read